Qihua Zhu

Dr. Qihua Zhu

Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSShi Shi
Shi Shi
YDYu Du
Yu Du
YZYi Zou
Yi Zou
JNJing Niu
Jing Niu
ZCZeyu Cai
Zeyu Cai
QZQihua Zhu
Qihua Zhu

1 September 2016 in Organic Letters
Verified
Journal Article
Closed access
DJDezhong Ji
Dezhong Ji
XHXin He
Xin He
YXYizhu Xu
Yizhu Xu
ZXZiyue Xu
Ziyue Xu
YBYuchen Bian
Yuchen Bian
JDJi Dezhong
Ji Dezhong

10 January 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SSShi Shi
Shi Shi
YDYu Du
Yu Du
LHLei Huang
Lei Huang
JCJiaqi Cui
Jiaqi Cui
JNJing Niu
Jing Niu
QZQihua Zhu
Qihua Zhu

23 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SWShuping Wang
Shuping Wang
YLYu Li
Yu Li
SHShi-Hui Huang
Shi-Hui Huang
SWShi-Qi Wu
Shi-Qi Wu
LGLing-Li Gao
Ling-Li Gao
JDJi Dezhong
Ji Dezhong

8 December 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SWShuping Wang
Shuping Wang
SWShi-Qi Wu
Shi-Qi Wu
SHShi-Hui Huang
Shi-Hui Huang
TYTang Yi xuan
Tang Yi xuan
LMLiu-Qiong Meng
Liu-Qiong Meng
JDJi Dezhong
Ji Dezhong
Inducing homologous-recombination (HR) deficiency is an effective strategy to broaden the indications of PARP inhibitors in the treatment of triple-negative breast cancer (TNBC). Herein, we find that repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FOXM1 inhibitor FDI-6 can sensitize BRCA-proficient TNBC to PARP inhibitor Olaparib in vitro and in vivo. Mechanistic studies show that Olaparib causes adaptive resistance by arresting the cell cycle at S and G2/M phases for HR repair, increasing the expression of CDK6, CCND1, CDK1, CCNA1, CCNB1, and CDC25B to promote cell cycle progression, and inducing the overexpression of FOXM1, PARP1/2, BRCA1/2, and Rad51 to activate precise repair of damaged DNA. FDI-6 inhibits the expression of FOXM1, PARP1/2, and genes involved in cell cycle control and DNA damage repair to sensitize TNBC cells to Olaparib by blocking cell cycle progression and DNA damage repair. Simultaneously targeting FOXM1 and PARP1/2 is an innovative therapy for more patients with TNBC.

22 February 2017 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
XHXin He
Xin He
YXYi-Zhu Xu
Yi-Zhu Xu
LKLing-Xuan Kong
Ling-Xuan Kong
HWHuan-Huan Wu
Huan-Huan Wu
DJDe-Zhong Ji
De-Zhong Ji
QZQihua Zhu
Qihua Zhu
An efficient and convenient method for the direct regioselective halogenation of 8-amidoquinolines has been developed. In the presence of CuX and N-fluorobenzenesulfonimide (NFSI), the C5-halogenation products of 8-acylaminoquinolines were obtained in moderate to excellent yields. This new procedure provides facile access to a variety of C5-halogenation of 8-amidoquinolines under mild conditions.